Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Gaffney

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
Rheumatology Advances in Practice|August 21, 2024
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritisJake Weddell, Stephanie R Harrison, Alexander N Bennett, et al.
Rheumatology (Oxford, England)|July 28, 2018
Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national registerGary J Macfarlane, Ross I R MacDonald, Ejaz Pathan, et al.
Rheumatology Advances in Practice|July 5, 2021
Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritisRebecca Pedley, Linda E Dean, Ernest Choy, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
Rheumatology (Oxford, England)|August 26, 2016
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologicsLouise Hamilton, Nick Barkham, Ashok Bhalla, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reductionRobert Bm Landewé, Désirée van der Heijde, Maxime Dougados, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
The Lancet. Rheumatology|June 28, 2024
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trialClaudia Worth, M Hussein Al-Mossawi, Joanne Macdonald, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
Rheumatology Advances in Practice|August 21, 2024
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritisJake Weddell, Stephanie R Harrison, Alexander N Bennett, et al.
Rheumatology (Oxford, England)|July 28, 2018
Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national registerGary J Macfarlane, Ross I R MacDonald, Ejaz Pathan, et al.
Rheumatology Advances in Practice|July 5, 2021
Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritisRebecca Pedley, Linda E Dean, Ernest Choy, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
Rheumatology (Oxford, England)|August 26, 2016
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologicsLouise Hamilton, Nick Barkham, Ashok Bhalla, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reductionRobert Bm Landewé, Désirée van der Heijde, Maxime Dougados, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
The Lancet. Rheumatology|June 28, 2024
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trialClaudia Worth, M Hussein Al-Mossawi, Joanne Macdonald, et al.
Pageof 8